Canada
· Delayed Price · Currency is CAD Avicanna Company Description
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide.
It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome.
It also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand.
In addition, the company operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, and educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens, as well as collaborates with public and private payers for adjudication and reimbursement.
The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator’s various drug delivery and pharmaceutical formats.
Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
| Country | Canada |
| Founded | 2016 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 87 |
| CEO | Aras Azadian |
Contact Details
Address: 480 University Avenue Toronto, Ontario M5G 1V2 Canada | |
| Phone | 647 243 5283 |
| Website | avicanna.com |
Stock Details
| Ticker Symbol | AVCN |
| Exchange | Toronto Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA05368K1003 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Aras Azadian B.Econ, Mba | Co-Founder, Chief Executive Officer and Director |
| Phillip Cardella C.A., CPA | Chief Financial Officer |
| Dr. Frantz Le Devedec | Executive Vice President of Research and Development |
| Stephen Kim | Chief Legal Officer and General Counsel of Avicanna USA Inc. |
| Arash Moghani MBA | Executive Vice President of Operations and Technology |
| Ingrid Diaz | Vice President, Assistant General Counsel and Corporate Compliance Officer |
| Ivana Maric | Executive Vice President of Marketing |
| Enric Pujol | Vice President of People |
| Dr. Carlos Enrique Maldonado Muete | SVice President of Clinical Development |
| Dr. Karolina Urban | Executive Vice President of Scientific and Medical Affairs |